Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2026 Mar 1;180(3):314-324.
doi: 10.1001/jamapediatrics.2025.5778.

Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children

Heidi L Moline  1   2 , Ayzsa Tannis  1 , Leah Goldstein  1 , Janet A Englund  3 , Mary A Staat  4   5 , Julie A Boom  6   7 , Rangaraj Selvarangan  8 , Marian G Michaels  9 , Geoffrey A Weinberg  10 , Natasha B Halasa  11 , Ariana P Toepfer  1 , Rachel E Rutkowski  1 , Abigail Salthouse  1 , Leila C Sahni  7   8 , Jennifer E Schuster  8 , Laura S Stewart  11 , John V Williams  9   12 , Daniel C Payne  4 , Eileen J Klein  3 , Peter G Szilagyi  10   13 , Fatimah S Dawood  1   2 ; New Vaccine Surveillance Network Collaborators
Collaborators, Affiliations
Multicenter Study

Effectiveness and Impact of Maternal RSV Immunization and Nirsevimab on Medically Attended RSV in US Children

Heidi L Moline et al. JAMA Pediatr. .

Erratum in

  • Error in Figure.
    [No authors listed] [No authors listed] JAMA Pediatr. 2026 Mar 1;180(3):348. doi: 10.1001/jamapediatrics.2026.0129. JAMA Pediatr. 2026. PMID: 41770556 Free PMC article. No abstract available.

Abstract

Importance: During the 2024-2025 respiratory syncytial virus (RSV) season in the US, nirsevimab and maternal RSV vaccination became widely available to prevent severe RSV disease in infants. Assessments of the real-world effectiveness and impact of both products are needed to inform RSV prevention policy.

Objectives: To estimate nirsevimab and maternal RSV vaccine effectiveness against medically attended RSV-associated acute respiratory illness (ARI) and to estimate the impact of these products on RSV-associated hospitalizations during 2024-2025.

Design, setting, and participants: Population-based surveillance for medically attended ARI was conducted among children younger than 2 years with systematic molecular testing for RSV. Children were enrolled at 7 US pediatric medical centers from October 1, 2024, through April 30, 2025. A test-negative case-control design was used to estimate maternal RSV vaccine and nirsevimab effectiveness.

Exposures: To estimate maternal RSV vaccine effectiveness, the exposure was maternal RSV vaccination among newborns and infants younger than 6 months at medical encounters; to estimate nirsevimab effectiveness, the exposure was nirsevimab receipt among newborns and infants younger than 8 months as of October 1, 2024, or born after that date.

Main outcomes and measures: The primary outcome was medically attended RSV-associated ARI and RSV-associated hospitalization. Immunization effectiveness was calculated as (1 - adjusted odds ratio) × 100%. To estimate population-level impact of RSV prevention products, relative rate reductions were estimated by comparing observed RSV-associated hospitalization rates during 2024-2025 to (1) observed rates in 2017-2020 or (2) counterfactual 2024-2025 rates estimated by a difference-in-differences approach; estimates from both approaches are presented as ranges.

Results: Overall, 5029 children younger than 2 years with medically attended ARI were enrolled during October 2024 to April 2025. Median (IQR) age was 10 months (5-16 months), and 2176 children (43.3%) were female. Among newborns and infants younger than 6 months, maternal RSV vaccine effectiveness was 64% (95% CI, 37%-79%) against any medically attended RSV-associated ARI and 70% (95% CI, 37%-86%) against RSV-associated hospitalization. Nirsevimab effectiveness was 81% (95% CI, 71%-87%) against RSV-associated hospitalization, and nirsevimab remained 77% (95% CI, 42%-92%) effective against RSV-associated hospitalization at 130 to 210 days after receipt. RSV-associated hospitalizations were reduced by 41% to 51% among newborns and infants aged 0 to 11 months, with the highest reduction of 56% to 63% in those aged 0 to 2 months.

Conclusions and relevance: According to the results of this population-based surveillance study, during 2024-2025, both maternal RSV vaccine and nirsevimab were estimated to be effective at protecting infants from RSV-associated hospitalizations in their first RSV season, and RSV-associated hospitalization rates in newborns and infants aged 0 to 11 months were reduced by up to half compared to seasons before these products were introduced.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Englund reported grants to her institution from the US Centers for Disease Control and Prevention (CDC) during the conduct of the study; personal fees from AstraZeneca, GlaxoSmithKline, Meissa, Merck, Moderna, Pfizer, and Shionogi; and grants to her institution from GlaxoSmithKline, Moderna, and Pfizer outside the submitted work. Dr Staat reported grants from the CDC during the conduct of the study and grants from Cepheid, Pfizer, and the US National Institutes of Health outside the submitted work. Dr Boom reported grant support to her institution from the CDC New Vaccine Surveillance Network during the conduct of the study. Dr Selvarangan reported grants from the CDC during the conduct of the study and grants from Altona, bioMérieux, Cepheid, Hologic, Meridian Bioscience, and Qiagen outside the submitted work. Dr Michaels reported funding for this study to her institution from the CDC during the conduct of the study and grants paid to her institution from Merck and the US National Institute of Allergy and Infectious Diseases outside the submitted work. Dr Weinberg reported research grants to his institution from the CDC during the conduct of the study; research grants to his institution from the New York State Department of Health (NYS DOH) AIDS Institute; personal fees from the NYS DOH AIDS Institute; honoraria for textbook chapters from Merck; and data and safety monitoring board and scientific advisory board fees from Emory University and Inhalon Biopharma, respectively, outside the submitted work. Dr Halasa reported grants from the CDC during the conduct of the study and grants from Merck and Sanofi outside the submitted work. Dr Sahni reported payment to her institution from the CDC during the conduct of the study and travel support from the Bill and Melinda Gates Foundation. Dr Schuster reported payment to her institution from the CDC during the conduct of the study. Dr Williams reported grants from the CDC during the conduct of the study and grants from the US National Institutes of Health outside the submitted work. Dr Payne reported personal fees from Merck during the conduct of the study. Dr Klein reported grants to her institution from the CDC during the conduct of the study. Dr Szilagyi reported grants from the CDC to the University of Rochester, which subcontracted the University of California, Los Angeles (his institution), during the conduct of the study. No other disclosures were reported.

References

    1. Suh M, Movva N, Jiang X, et al. Respiratory syncytial virus is the leading cause of United States infant hospitalizations, 2009-2019: a study of the national (nationwide) inpatient sample. J Infect Dis. 2022;226(suppl 2):S154-S163. doi: 10.1093/infdis/jiac120 - DOI - PMC - PubMed
    1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598. doi: 10.1056/NEJMoa0804877 - DOI - PMC - PubMed
    1. Shi T, McAllister DA, O’Brien KL, et al. ; RSV Global Epidemiology Network . Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958. doi: 10.1016/S0140-6736(17)30938-8 - DOI - PMC - PubMed
    1. Curns AT, Rha B, Lively JY, et al. Respiratory syncytial virus-associated hospitalizations among children <5 years old: 2016 to 2020. Pediatrics. 2024;153(3):e2023062574. doi: 10.1542/peds.2023-062574 - DOI - PubMed
    1. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122. doi: 10.15585/mmwr.mm7241e1 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances